Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 120 participants.
Also called NCT01664637
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Tranzyme, Inc.
- Registry
-
NCT01664637
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Poland
- Registry status
- Terminated
Technical summary
Registry record NCT01664637. Randomized; quadruple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
- Acronym
- DIGEST
- Condition
- Diabetic Gastroparesis
- Intervention (Drug)
- 10 mg TZP-102
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tranzyme, Inc.
Record details
- Record id
cardio:ct-nct01664637- Content hash
c2d5f8bc13c84935d87193c693a87bda71454df8fcfb4954e37d1e926e6c60ef